Related Experiment Video
Updated: Jun 11, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Soluble CD146 reflects altered endothelial and metabolic homeostasis in peripheral artery disease
Haizam Oubari1,2, Julien Labreuche3, Charlotte Reytier4
1Center for Engineering in Medicine and Surgery, Department of Surgery, Harvard Medical School, Massachusetts General Hospital, États-Unis, Boston, MA, États-Unis d'Amérique.
Background:
Peripheral Arterial Disease (PAD) is a prevalent but underdiagnosed pathology. Soluble CD146 (sCD146) was described as a marker of endothelial dysfunction and vascular congestion.
Objective:
We hypothesize that sCD146 may represent a novel biomarker of PAD. Our objective was to evaluate the association between plasma sCD146 levels and the occurrence and severity of PAD.
Methods:
In this case-control study, 184 Caucasian men with symptomatic PAD were compared to 163 age-matched healthy control patients. PAD diagnosis was confirmed using ankle-brachial index (ABI) and imaging. Plasma sCD146 was quantified using ELISA. Associations with clinical and biochemical parameters were analyzed through multivariable logistic regression models.
Results:
sCD146 level was significantly reduced in PAD patients (mean [95% CI]: 288 ng/mL [269-306]) versus control patients (480 ng/mL [460-500], p < 0.0001). A 10 ng/mL decrease in sCD146 was associated with an age-adjusted odds ratio (OR) of 1.17 (95% CI 1.13-1.22) for PAD, increasing to OR 1.25 (95% CI 1.14-1.36, p < 0.0001) after adjustment for risk factors. sCD146 was not associated with PAD severity (by Fontaine stage). Notably, the association between sCD146 and HDL-C was positively correlated in controls (β = 0.220, p = 0.005), but negatively correlated in PAD patients (β = - 0.156, p = 0.041), with significant interaction (p = 0.002). Age-adjusted OR for PAD was highest in individuals with high HDL-C tertiles (OR = 1.41, 95% CI 1.22-1.63).
Conclusion:
A lower sCD146 concentration is independently associated with PAD. Additionally, an inverse relationship was observed between HDL-C and these patients. These findings suggest that sCD146 may reflect impaired endothelial homeostasis and metabolic dysregulation in PAD, indicating that it could serve as a diagnostic biomarker for the pathology.
Clinical Trials Registration:
NCT00377897.
Insights
Lower levels of soluble CD146 (sCD146) are associated with Peripheral Arterial Disease (PAD). This finding suggests sCD146 may be a novel diagnostic biomarker for PAD, reflecting endothelial dysfunction.
Area of Science:
- Cardiovascular Research
- Biomarker Discovery
- Endothelial Function
Background:
- Peripheral Arterial Disease (PAD) is common and often underdiagnosed.
- Soluble CD146 (sCD146) is linked to endothelial dysfunction and vascular congestion.
Purpose of the Study:
- To investigate soluble CD146 (sCD146) as a potential novel biomarker for Peripheral Arterial Disease (PAD).
- To assess the association between plasma sCD146 levels and PAD occurrence and severity.
Main Methods:
- A case-control study compared 184 symptomatic PAD patients with 163 healthy controls.
- PAD diagnosis was confirmed via ankle-brachial index (ABI) and imaging.
- Plasma sCD146 levels were measured using ELISA, with associations analyzed via multivariable logistic regression.
Main Results:
- sCD146 levels were significantly lower in PAD patients (288 ng/mL) compared to controls (480 ng/mL).
- Each 10 ng/mL decrease in sCD146 increased PAD odds by 1.25 (OR, 95% CI 1.14-1.36).
- sCD146 levels did not correlate with PAD severity but showed an inverse relationship with HDL-C in PAD patients.
Conclusions:
- Lower plasma sCD146 concentration is independently associated with PAD.
- The findings suggest sCD146 may indicate impaired endothelial homeostasis and metabolic issues in PAD.
- sCD146 shows potential as a diagnostic biomarker for Peripheral Arterial Disease.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction
Coronary Artery Disease I: Introduction
